Market Reports

Manufacturing vaccines, digital twins and lessons learned: part I

Using a digital replica of the manufacturing process, the pharmaceutical industry is exploring the ability of virtual technology to improve the efficiency and agility of the production chain and expedite time-to-market

Using ddPCR to accurately quantify AAV viral titre and integrity

Gene therapy is primed to become the next major development in medicine and bring relief to patients living with diseases ranging from haemophilia to Alzheimer’s disease, write Mark White, Associate Director of Biopharma Product Marketing, and Marwan Alsarraj, Biopharma Segment Manager, Bio-Rad

Opportunities to scale AAV viral vector production for gene therapies

Gene therapies hold tremendous potential as a treatment modality for inherited human diseases. This emerging therapeutic approach can correct or replace pathologic mutations, inactivate mutated genes that are functioning improperly and also introduce new genes to help our bodies fight diseases. Thermo Fisher Scientific's Mike Brewer and Alejandro Becerra report

Big names confirmed to speak at Manufacturing Chemist Live

NASA and AstraZeneca have joined the extensive list of speakers for the combined virtual and in-person event

Refining test methods for a new generation of nasal drug products

The nasal drug product market is currently the focus of considerable research activity. Nasal sprays for local action, such as the treatment of illnesses including allergic rhinitis and hay fever, dominate in terms of market volume and are an important target for generic manufacturers, report Anna Sipitanou, Business Development Manager, and Mark Copley, CEO, Copley Scientific

Taking a holistic approach to quality management

Ensuring quality is one of the most important tasks for bio/pharmaceutical innovators and their external partners. This is vital to keep patients safe and healthy, as well as avoid unnecessary regulatory delays during the development process

Real world evidence: helping to end COVID-19 disruption

Truly bringing the COVID-19 pandemic under control will take concerted efforts beyond the rollout of a global mass vaccination programme. Understanding the real-world performance of vaccines and treatments has a key part to play to identify how and when improvements can be made to enhance their effectiveness in the future

Manufacturing Chemist Live: A hybrid event

Taking place on 14-15 September, the event will put delegates ahead of the curve in the global pharmaceutical supply chain

Pure, smooth and strong

The EVERIC range of pharmaceutical vials from SCHOTT meets the challenges of today’s fill and finish lines

Pharmaceutical reshoring: a healthy requirement, a strategic necessity

More than a year into the COVID-19 crisis, the novel coronavirus continues to disrupt our societies, including how the pharmaceutical industry operates; Andrew Badrot, CEO of C<sup>2</sup> PHARMA, discusses the ongoing ramifications of the pandemic

Taking a lifecycle approach to fill-finish success

Dr Kevin Robinson recently spoke to swissfillon founder and CEO, Daniel Kehl, and Business Development Director, Carole Delauney, to discuss the company’s baptism by fire during the COVID-19 pandemic and how they can help companies succeed in the pharmaceutical industry’s “new normal”

Lessons learned from the COVID-19 pandemic

As vaccines roll out and COVID-19 cases begin to decline, Amélie Boulais, Head of Market Entry Strategy for Virus Based Therapeutics at Sartorius, reflects on key takeaways that will impact the biopharmaceutical industry’s approach to pandemic preparedness in 2021 and beyond

Harnessing the power of HPAPIs: key considerations

Adam Kujath, Senior Director at Sterling Pharma Solutions, discusses the key issues that companies need to consider when embarking on an HPAPI project. He also outlines what can go wrong if the right steps are not taken to ensure effective containment and gives insight into how access to the right expertise can help to accelerate timelines

From dark art to an age of enlightenment

Much is happening in the realms of Almac’s GMP peptides business in terms of growth, development and strategic operations. And, with the company’s current focus on neoantigen-derived vaccines that harness the body’s own immune system to fight cancer, Dr Kevin Robinson zoomed in to find out more

The application of picodroplet technology for biopharmaceutical discovery and scientific research

Picodroplet technologies continue to push the boundaries of biologic discovery by accelerating research, expanding the scope of exploration and reducing drug discovery and development costs, explains Olivia Hughes, Senior Marketing Associate at Sphere Fluidics

Plastic pallets and the COVID response

Jim Hardisty explores the logistical challenges of distributing the COVID vaccine, how Goplasticpallets.com has been supporting the COVID response and why selecting the right pallet for your application is crucial

Derisking topical formulation development with multifactorial disease models

Today’s market for topical pharmaceuticals is valued at around $95 billion, with development efforts focused on small molecules and biologics. Forecast to grow by $70 billion during the next 4–5 years, this is a fast-moving area in which cost-effective development is essential, report Dr Jon Lenn, Chief Technology Officer, and Prof. Marc Brown, Chief Scientific Officer and Cofounder, MedPharm

Traceability: the backbone of the pharmaceutical supply chain

The pharmaceutical industry is one in which speed and quality are essential ingredients to a successful business. The proper software ensures suppliers become a force to help, not hinder, these factors, explains Andrew Bray, Managing Director, K3

The increasing power of single-cell omics: changing the future of medicine

Advances in the single-cell genomic analysis of cells and tissues, including the required computational methods, have now put systematic, high-resolution and comprehensive reference maps of all human cells within our reach. Paradigm4's Marilyn Matz, CEO and cofounder, and Dr Zachary Pitluk, VP of Life Sciences and Healthcare, report

Drug dose delivery development, manufacturing and commercialisation trends: part II

In the wake of patient-centricity in the pharmaceutical industry, drug delivery technologies have emerged as a central driver of therapeutic and patient success. Dr Kevin Robinson went online with Manuel Leal, Business Development Director, Idifarma, Steve Rode, Manager Business Development, Capsules and Health Ingredients, Lonza, and John Ross, President, Mayne Pharma US/Metrics Contract Services, to find out more

Technology to transform the capture and processing of drug safety data

The ultimate goal of pharmacovigilance is to prevent adverse drug reactions, thus maximising the benefit:risk ratio for as many patients as possible, reports Dr Andrew Rut, CEO and founder, MyMeds&Me

Navigating the sea change of pharmaceutical outsourcing: part II

After what has oft-been described as an unprecedented period of turbulence in almost every aspect of our everyday lives, Dr Kevin Robinson sat down with experts from a number of pharmaceutical contract development and manufacturing organisations (CDMOs) to discuss how the events of the past year have affected the activity and outlook of the industry’s outsourcing sector

Real-time monitoring of pharmaceutical coatings by optical coherence tomography (OCT)

The coating process is the last step of tablet production and thus influences some of the critical quality attributes (CQAs) of these oral solid dosage forms. RCPE's Stephan Sacher, Senior scientist, Process and Manufacturing Science, Matthias Wolfgang, Scientist, Process and Manufacturing Science, Anna Peter, Scientist, Process and Manufacturing Science, Sandra Stranzinger, Senior scientist, Advanced Products and Delivery, and Johannes Khinast, CEO and Scientific Director, explain

Moulded glass vials secure COVID-19 vaccine supply

Although different materials have been trialled and tested, glass remains the most widely used type of primary container for parenteral drug products, writes Dr Jingwei Zhang, R&D Director, SGD Pharma

Trending Articles

  1. The economic advantages of continuous flow chemistry Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit
  2. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  3. Peak identification by LC/MS: Automation versus analyst High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
  4. Poolbeg granted FDA Orphan Drug Designation for POLB 001 The US FDA grants orphan status to support the development of medicines for rare disorders affecting fewer than 200,000 people in the US
  5. Rare diseases: understanding the patient journey In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research

Upcoming event

BIO International Convention

3-6 June, 2024 | Convention | Boston, US See all